INSERM U1016, Cochin Institute, Faculté de Médecine, Université Paris Descartes, Sorbonne Paris Cité, Paris, France.
IMAGINE Institute affiliate, Paris, France.
Eur J Endocrinol. 2020 Nov;183(5):K1-K5. doi: 10.1530/EJE-20-0255.
Among patients with congenital hypothyroidism, 35% have dyshormonogenesis (DH) with thyroid gland in situ with or without goiter. The majority of DH cases are due to mutations in genes involved in thyroid hormone production as TG, TPO, SLC5A5/NIS, SLC26A4/PDS, IYD/DEHAL1, DUOX2, and DUOXA2, and are usually inherited on an autosomal recessive basis. Most previously reported cases of fetal hypothyroidism and goiter were related to TG or TPO mutations and recently DUOXA2.
In a male patient with antenatal goiter treated with intraamniotic levothyroxine injections, whose long-term follow-up is described in detail, two novel NIS mutations were detected. Mutations of NIS were located in exon 1 (c.52G>A, p.G18R) and exon 13 (c.1546C>T, p.R516X), each mutation was inherited from parents, who are healthy carriers. The p.G18R mutation affecting the first transmembrane domain of the protein can be responsible for deficient iodide uptake. However, the second is a nonsense mutation leading probably to mRNA degradation. In addition, the patient has undergone a thyroidectomy and we have studied the thyroid tissue. The thyroid histology showed heterogeneity with large follicles, epithelial hyperplasia and many areas of fibrosis. Immunohistochemistry with NIS specific antibody showed NIS staining at the basolateral plasma membrane of the thyrocytes.
We report the first case of fetal goitrous hypothyroidism due to two novel NIS mutations with access to thyroid tissue of the patient, specific histology studies and long-term follow-up. This case expands our knowledge and provides further insights on molecular causes of fetal goiter in humans.
在先天性甲状腺功能减退症患者中,有 35%的患者存在甲状腺原位的激素生成障碍(DH),伴或不伴甲状腺肿。大多数 DH 病例是由于甲状腺激素生成相关基因的突变引起的,如 TG、TPO、SLC5A5/NIS、SLC26A4/PDS、IYD/DEHAL1、DUOX2 和 DUOXA2,这些突变通常是常染色体隐性遗传的。以前报道的大多数胎儿甲状腺功能减退和甲状腺肿病例与 TG 或 TPO 突变有关,最近与 DUOXA2 有关。
一名男性患者,产前甲状腺肿,接受羊膜内左旋甲状腺素注射治疗,其长期随访情况详细描述,发现了两种新的 NIS 突变。NIS 突变位于外显子 1(c.52G>A,p.G18R)和外显子 13(c.1546C>T,p.R516X),每个突变均由健康携带者的父母遗传。影响蛋白第一跨膜结构域的 p.G18R 突变可导致碘摄取缺陷。然而,第二个是无义突变,可能导致 mRNA 降解。此外,患者已行甲状腺切除术,我们研究了甲状腺组织。甲状腺组织学显示不均质性,大滤泡、上皮增生和许多纤维化区域。用 NIS 特异性抗体进行的免疫组织化学染色显示,甲状腺细胞的基底外侧质膜有 NIS 染色。
我们报告了首例由于两个新的 NIS 突变导致的胎儿甲状腺肿性甲状腺功能减退症病例,可获得患者的甲状腺组织、特定的组织学研究和长期随访。该病例扩展了我们的知识,并为人类胎儿甲状腺肿的分子病因提供了进一步的见解。